Custom Search


Portfolio of Cancer Immunotherapy Stocks

Here are 24 cancer immunotherapy stocks.

Cancer Immunotherapy Stocks
Stock
Price Quote & Dividend
1-Yr Price Chart
Amgen
AstraZeneca
BeiGene, Ltd. 
Bellicum Pharmaceuticals
bluebird bio
Bristol-Myers Squibb
Celgene
Celldex Therapeutics
Cellectis
Celyad
Clovis Oncology
Compugen Ltd.
Curis
CytomX Therapeutics
Five Prime Therapeutics
Gilead Sciences
Incyte Corporation
Loncar Cancer Immunotherapy ETF
Merck
NantKwest
Nektar Therapeutics
Novartis
Pfizer
ZIOPHARM Oncology
Price and dividend data from Quandl.


To inspect the performance of the Cancer Immunotherapy Stocks portfolio, see the returns table and chart below. Portfolio values are computed using quarterly closes for from Quandl.

The 14 included in the portfolio computations are: AMGN, AZN, BMY, CELG, CLDX, CGEN, CRIS, GILD, INCY, MRK, NKTR, NVS, PFE and ZIOP. The current value of the portfolio assumes that $714.29 was invested (total of $10,000) in each at its closing weekly price for the current date in 2008. The 10 excluded from the portfolio computations because of insufficient price data are: BGNE, BLCM, BLUE, CLLS, CYAD, CLVS, CTMX, FPRX, CNCR and NK.


Cancer Immunotherapy Stocks - Return Results
Portfolio:
Cancer Immunotherapy Stocks
Start date:
Feb-21-2008
Start value:
$10,000
End date:
Feb-21-2018
End value:
$35,246
Number prices
121
Minimum value occurred on Feb-28-2009
$6,752
Maximum value occurred on Jul-31-2015
$36,678
Total gain or loss (Start date to End date)
252.46%
Annualized gain or loss (Start date to End date)
13.43%
Total dollar value on End date of a $10,000 purchase made on Start date
$35,246
Average percent return for all possible buy/sell combinations
89.46%
Number returns
7,260
Number profitable returns (Winners)
6,488
Percent profitable returns
89.37%
Number unprofitable returns (Losers)
772
Percent unprofitable returns
10.63%
Winners to losers ratio
8.40
Stock Return Calculator






Related Articles

Portfolio of Big Pharmaceuticals Stocks: Cancer
Portfolio of Biotech Stocks: Cancer
Portfolio of Immune Checkpoint Inhibitor Stocks